Eli Lilly's Ixekizumab Met Primary Endpoint In Patients With Plaque Psoriasis - NASDAQ

Eli Lilly's Ixekizumab Met Primary Endpoint In Patients With Plaque disease of the skin NASDAQ (LLY) said that new Phase II data, published in the brand-new England Journal of Medicine, showed that the Company's ixekizumab, an anti-IL-17 being antibody, met its capital endpoint in patients with moderate-to-severe plaque psoriasis , ... Link To Article